Intelgenx Technologies CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
IntelGenx Technologies Corp. has filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code.
IntelGenx Technologies Corp. completed a restructuring under the Companies' Creditors Arrangement Act, resulting in the acquisition of its subsidiary by atai Life Sciences and the resignation of key executives and board members.
IntelGenx Technologies Corp. is moving forward with a sale transaction with atai Life Sciences AG after the initial bidding process did not yield superior offers.
IntelGenx Technologies Corp. has received court approval to begin a sale and investment solicitation process, aiming to find a buyer for the business or assets, or to recapitalize the company.
IntelGenx Technologies Corp. has commenced restructuring proceedings under the Companies' Creditors Arrangement Act (CCAA) due to a liquidity crisis and delays in regulatory approvals.
IntelGenx Technologies Corp. successfully held its annual shareholder meeting, electing eight directors and approving the appointment of auditors, executive compensation, and unallocated share units.
IntelGenx Technologies Corp. has entered into a third amended loan agreement with Atai Life Sciences AG, securing a $2 million loan and issuing warrants for the purchase of common stock.
IntelGenx Technologies Corp. has entered into a selling agency agreement with Digital Offering, LLC for a best efforts offering of up to 2,000,000 shares of convertible preferred stock and up to 40,000,000 shares of common stock.
IntelGenx Technologies Corp. has created and issued 2,090,000 shares of Series A Convertible Cumulative Preferred Stock, which have preferential rights over common stock.